Latin America steps towards common medtech market with Mercosur GMP move
This article was originally published in Clinica
Executive Summary
In a significant move for medtech manufacturing across Latin America, the Mercosur trading bloc has approved measures to harmonise the inspection and certification of manufacturers of medical devices and in vitro diagnostics. The bloc’s five member states – Argentina, Brazil, Paraguay, Uruguay and Venezuela – are to transpose a series of good-manufacturing practice (GMP) compliance procedures into national law by the end of April 2013.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.